149 related articles for article (PubMed ID: 16782211)
21. An animal model of antipsychotic-induced weight gain.
Arjona AA; Zhang SX; Adamson B; Wurtman RJ
Behav Brain Res; 2004 Jun; 152(1):121-7. PubMed ID: 15135975
[TBL] [Abstract][Full Text] [Related]
22. Betahistine co-treatment ameliorates dyslipidemia induced by chronic olanzapine treatment in rats through modulation of hepatic AMPKα-SREBP-1 and PPARα-dependent pathways.
Liu X; Lian J; Hu CH; Deng C
Pharmacol Res; 2015 Oct; 100():36-46. PubMed ID: 26218603
[TBL] [Abstract][Full Text] [Related]
23. Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain.
Cooper GD; Harrold JA; Halford JC; Goudie AJ
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):428-36. PubMed ID: 17933447
[TBL] [Abstract][Full Text] [Related]
24. Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats.
Choi S; DiSilvio B; Unangst J; Fernstrom JD
Life Sci; 2007 Sep; 81(12):1024-30. PubMed ID: 17822717
[TBL] [Abstract][Full Text] [Related]
25. Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat.
Smith GC; Vickers MH; Shepherd PR
Arch Physiol Biochem; 2011 Oct; 117(4):241-9. PubMed ID: 21671852
[TBL] [Abstract][Full Text] [Related]
26. Olanzapine-activated AMPK signaling in the dorsal vagal complex is attenuated by histamine H1 receptor agonist in female rats.
He M; Zhang Q; Deng C; Wang H; Huang XF
Endocrinology; 2014 Dec; 155(12):4895-904. PubMed ID: 25264935
[TBL] [Abstract][Full Text] [Related]
27. A model for antipsychotic-induced obesity in the male rat.
Minet-Ringuet J; Even PC; Lacroix M; Tomé D; de Beaurepaire R
Psychopharmacology (Berl); 2006 Sep; 187(4):447-54. PubMed ID: 16783538
[TBL] [Abstract][Full Text] [Related]
28. Body weights and plasma prolactin levels in female rats treated subchronically with ziprasidone versus olanzapine.
Kalinichev M; Rourke C; Jones DN
Behav Pharmacol; 2006 May; 17(3):289-92. PubMed ID: 16572006
[TBL] [Abstract][Full Text] [Related]
29. Discovery of a novel non-steroidal GR antagonist with in vivo efficacy in the olanzapine-induced weight gain model in the rat.
Hunt HJ; Ray NC; Hynd G; Sutton J; Sajad M; O'Connor E; Ahmed S; Lockey P; Daly S; Buckley G; Clark RD; Roe R; Blasey C; Belanoff J
Bioorg Med Chem Lett; 2012 Dec; 22(24):7376-80. PubMed ID: 23131342
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of olanzapine-induced weight gain by the retinoid analog AM-80.
Richards M; Chiba S; Ninomiya M; Wakabayasi C; Kunugi H
Pharmacopsychiatry; 2013 Nov; 46(7):267-73. PubMed ID: 24105080
[TBL] [Abstract][Full Text] [Related]
31. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
[TBL] [Abstract][Full Text] [Related]
32. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
[TBL] [Abstract][Full Text] [Related]
33. A role for hypothalamic AMP-activated protein kinase in the mediation of hyperphagia and weight gain induced by chronic treatment with olanzapine in female rats.
Sejima E; Yamauchi A; Nishioku T; Koga M; Nakagama K; Dohgu S; Futagami K; Kataoka Y
Cell Mol Neurobiol; 2011 Oct; 31(7):985-9. PubMed ID: 21681559
[TBL] [Abstract][Full Text] [Related]
34. Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents.
Albaugh VL; Henry CR; Bello NT; Hajnal A; Lynch SL; Halle B; Lynch CJ
Obesity (Silver Spring); 2006 Jan; 14(1):36-51. PubMed ID: 16493121
[TBL] [Abstract][Full Text] [Related]
35. Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat.
Davey KJ; Cotter PD; O'Sullivan O; Crispie F; Dinan TG; Cryan JF; O'Mahony SM
Transl Psychiatry; 2013 Oct; 3(10):e309. PubMed ID: 24084940
[TBL] [Abstract][Full Text] [Related]
36. Metabolic side effects induced by olanzapine treatment are neutralized by CB1 receptor antagonist compounds co-administration in female rats.
Lazzari P; Serra V; Marcello S; Pira M; Mastinu A
Eur Neuropsychopharmacol; 2017 Jul; 27(7):667-678. PubMed ID: 28377074
[TBL] [Abstract][Full Text] [Related]
37. Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution.
van der Zwaal EM; Luijendijk MC; Adan RA; la Fleur SE
Eur J Pharmacol; 2008 May; 585(1):130-6. PubMed ID: 18378227
[TBL] [Abstract][Full Text] [Related]
38. A comparison of the effects of olanzapine and risperidone versus placebo on ghrelin plasma levels.
Roerig JL; Steffen KJ; Mitchell JE; Crosby RD; Gosnell BA
J Clin Psychopharmacol; 2008 Feb; 28(1):21-6. PubMed ID: 18204336
[TBL] [Abstract][Full Text] [Related]
39. Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways.
Lian J; Huang XF; Pai N; Deng C
Psychoneuroendocrinology; 2014 Oct; 48():77-86. PubMed ID: 24992721
[TBL] [Abstract][Full Text] [Related]
40. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
Wu RR; Zhao JP; Guo XF; He YQ; Fang MS; Guo WB; Chen JD; Li LH
Am J Psychiatry; 2008 Mar; 165(3):352-8. PubMed ID: 18245179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
